Patents Examined by Kimberly A Aron
  • Patent number: 11432537
    Abstract: The present invention discloses a novel means capable of producing a blood chimeric animal in which a state of retaining blood cells originating in a heterologous animal at a high percentage is sustained for a long period of time. The method for producing a non-human animal that retains blood cells originating in a heterologous animal, according to the present invention, comprises transplanting hematopoietic cells of a heterologous animal into a non-human animal, in which hematopoietic cells the function of a gene that acts on the hematopoietic system is modified, The gene that acts on the hematopoietic system is, for example, Lnk gene, When a medium to large mammal is used as a recipient, the survival rate of hematopoietic cells originating in a heterologous animal is dramatically increased such that blood chimerism of 10% or more can be maintained even in a 16 month old animal.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: September 6, 2022
    Assignees: THE UNIVERSITY OF TOKYO, NATIONAL FEDERATION OF AGRICULTURAL COOPERTIVE ASSOCIATIONS
    Inventors: Kazuo Fukawa, Tetsuya Ito, Mai Kamikawa, Yutaka Sendai, Hiromitsu Nakauchi, Satoshi Yamazaki, Motoo Watanabe
  • Patent number: 11426469
    Abstract: The disclosure relates to compositions and methods for rAAV-mediated delivery of a transgene to a subject. In some embodiments, the rAAV transduces the prostate tissue of a subject. In some embodiments, the methods are useful for treatment of prostate disease (e.g., prostatitis, BPH, prostate cancer).
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: August 30, 2022
    Assignee: University of Massachusetts
    Inventors: Guangping Gao, Jianzhong Ai, Hong Li, Qiang Wei
  • Patent number: 11407996
    Abstract: A gene vector for use in gene therapy comprising at least one miRNA sequence target operably linked to a nucleotide sequence having a corresponding miRNA in a hematopoietic progenitor cell (HSPC) or hematopoietic stem cell (HSC) which prevents or reduces expression of the nucleotide sequence in a HSPC or HSC but not in a differentiated cell.
    Type: Grant
    Filed: April 15, 2019
    Date of Patent: August 9, 2022
    Assignees: Ospedale San Raffaele S.r.l., Fondazione Telethon
    Inventors: Alessandra Biffi, Bernhard Rudolf Gentner, Luigi Naldini
  • Patent number: 11407812
    Abstract: Certain embodiments of the invention provide a method of treating an excitable cell-related disease or condition in a mammal in need thereof, comprising administering to the mammal an effective amount of a vector comprising an expression cassette, wherein the expression cassette comprises a promoter operably linked to a nucleic acid encoding a subunit of a multimeric ion channel.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: August 9, 2022
    Assignee: GOLEINI INC.
    Inventors: Griffith Roger Thomas, Shawnalea Jimee Frazier
  • Patent number: 11396662
    Abstract: The present invention provides polynucleotide vectors for high expression of heterologous genes. Some vectors further comprise novel transposons and transposases that further improve expression. Further disclosed are vectors that can be used in a gene transfer system for stably introducing nucleic acids into the DNA of a cell. The gene transfer systems can be used in methods, for example, gene expression, bioprocessing, gene therapy, insertional mutagenesis, or gene discovery.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: July 26, 2022
    Assignee: DNA TWOPOINTO INC.
    Inventors: Jeremy Minshull, Sridhar Govindarajan, Maggie Lee
  • Patent number: 11357870
    Abstract: The present disclosure provides codon optimized nucleotide sequences encoding human REP1, vectors, and host cells comprising codon optimized REP1 sequences, and methods of treating retinal disorders such as choroideremia comprising administering to the subject a codon optimized sequence encoding human REP1.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: June 14, 2022
    Assignee: 4D Molecular Therapeutics Inc.
    Inventors: David H. Kirn, Melissa A. Kotterman, Peter Francis
  • Patent number: 11326184
    Abstract: Methods and compositions are provided for making one or more targeted genetic modifications at a target genomic locus within a cell and for producing non-human animals comprising the modified genomic locus. The methods employ two or more large targeting vectors which are capable of recombining with each other and with the target genomic locus in a single genomic targeting step. The methods may also be employed in combination with a nuclease agent. Methods and compositions are also provided for enhancing homologous recombination at a target genomic locus in a cell. The methods employ two or more nucleic acids comprising one or more overlapping sequences. The methods may be employed in combination with a nuclease agent or without a nuclease agent.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: May 10, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Vera Voronina, Lynn Macdonald, Brian Zambrowicz, Andrew J. Murphy
  • Patent number: 11318166
    Abstract: Described herein are methods and compositions using PTH and mesenchymal stem cells (MSCs) for treatment of osteoporosis, bone fractures, and related conditions. Administration of both PTH and MSCs leads to increased homing of MSCs to sites of vertebral bone and rib fracture. The described methods and compositions provide therapeutic approaches that rely, in-part, on stem cell capacity for regeneration and repair. The potential for enhanced bone formation and fracture repair may allow for both preventative and palliative treatments in osteoporotic patients, with combined PTH+MSC therapy producing bone regeneration capacity that is significantly superior to either treatment alone.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: May 3, 2022
    Assignee: Cedars-Sinai Medical Center
    Inventors: Dan Gazit, Edward M. Schwarz, Hyun Bae, Gadi Pelled, Zulma Gazit, Dmitriy Sheyn, Wafa Tawackoli
  • Patent number: 11312936
    Abstract: The specification describes a composition comprising an improved eukaryotic cell culture medium, which can be used for the production of a protein of interest. Taurine can be added to serum-free media or chemically-defined media to increase the production of a protein of interest. Methods for recombinantly expressing high levels of protein using the media compositions are included.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: April 26, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Amy S. Johnson, Meghan E. Casey, Shadia Oshodi, Shawn Lawrence
  • Patent number: 11306291
    Abstract: The present invention relates to production of proteins in insect cells whereby repeated coding sequences are used in baculoviral vectors. In particular the invention relates to the production of parvoviral vectors that may be used in gene therapy and to improvements in expression of the viral rep proteins that increase the productivity of parvoviral vectors.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: April 19, 2022
    Assignee: UNIQURE IP B.V.
    Inventors: Andrew Christian Bakker, Wilhelmus Theodorus Johannes Maria Christiaan Hermens
  • Patent number: 11297829
    Abstract: The present invention relates generally to systems and methods for preparing, storing, shipping and using skin equivalents made by organotypic culture. In particular, the present invention relates to systems and methods for cryopreserving viable skin substitutes.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: April 12, 2022
    Assignee: Stratatech Corporation
    Inventors: B. Lynn Allen-Hoffmann, John C. Pirnstill, Kenneth R. Gratz, Allen R. Comer
  • Patent number: 11285168
    Abstract: Tumor growth was found to be significantly suppressed in vivo by inhibiting both miRNA containing 5?-AACACUG-3? as a seed sequence and miRNA containing 5?-AAUACUG-3? as a seed sequence. The inhibition significantly altered the proportion of subpopulations of tumor cells and reduced the tumorigenicity in all subpopulations. The inhibition also exerted a remarkable tumor-shrinking effect on already-formed tumors. The present invention provides novel therapeutic potential against tumor.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: March 29, 2022
    Assignee: NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY
    Inventors: Hideo Iba, Takeshi Haraguchi
  • Patent number: 11279745
    Abstract: The present invention relates to plasmids useful for prevention and/or delay of e.g. type 1 diabetes.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: March 22, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Jay Chaplin, Michael Wijaranakula
  • Patent number: 11253576
    Abstract: In some aspects, the disclosure relates to compositions and methods useful for the diagnosis and treatment of neurodegenerative diseases, such as leukodystrophies (e.g., Canavan Disease). In some embodiments, the methods comprise administering to a subject an N-acetylaspartate (NAA)-depleting agent or an N-acetylaspartate (NAA)-depleting agent based upon the subject's metabolic profile.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: February 22, 2022
    Assignee: University of Massachusetts
    Inventors: Guangping Gao, Dominic Gessler
  • Patent number: 11248209
    Abstract: This invention provides methods to prepare and use immunostimulatory cells for enhancing an immune response. The invention provides a method for preparing mature dendritic cells (DCs), comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) with a first signal comprising an interferon gamma receptor (IFN-?R) agonist and/or a tumor necrosis factor alpha receptor (TNF-?R) agonist to produce signaled dendritic cells; and (b) signaling said signaled dendritic cells with a second transient signal comprising an effective amount of a CD40 agonist to produce CCR7+ mature dendritic cells. Also provided by this invention are enriched populations of dendritic cells prepared by the methods of the invention. Such dendritic cells have enhanced immunostimulatory properties and increased IL-12 secretion and/or decreased IL-10 secretion. CD40 signaling can be initiated by one or more of polypeptide translated from an exogenous polynucleotide encoding CD40L (e.g.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: February 15, 2022
    Assignee: CoImmune, Inc.
    Inventors: Don Healey, Irina Tcherepanova, Melissa Adams
  • Patent number: 11234419
    Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion in an immunoglobulin constant region CH1 gene (optionally a deletion in a hinge region) of an IgG, IgA, IgD, and/or IgE, and wherein the mouse is capable of expressing a functional IgM. Genetically modified mice are described, including mice having a functional IgM gene and modified to have a deletion of a CH1 domain and a hinge region in a heavy chain constant domain that is not an IgM, e.g., in an IgG heavy chain constant domain. Genetically modified mice that make human variable/mouse constant chimeric heavy chain antibodies (antibodies that lack a light chain), fully mouse heavy chain antibodies, or fully human heavy chain antibodies are provided.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: February 1, 2022
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: Lynn Macdonald, Sean Stevens, Andrew J. Murphy
  • Patent number: 11224207
    Abstract: Genetically modified non-human animals are provided that express an immunoglobulin variable domain that comprises at least one histidine, wherein the at least one histidine is encoded by a substitution of a non-histidine codon in the germline of the animal with a histidine codon, or the insertion of a histidine codon in a germline immunoglobulin nucleic acid sequence. Immunoglobulin genes comprising histidines in one or more CDRs, in an N-terminal region, and/or in a loop 4 region are also provided. Immunoglobulin variable domains comprising one or more histidines (e.g., histidine clusters) substituted for non-antigen-binding non-histidine residues. Non-human animals that are progeny of animals comprising modified heavy chain variable loci (V, D, J segments), modified light chain variable loci (V, J segments), and rearranged germline light chain genes (VJ sequences) are also provided. Non-human animals that make immunoglobulin domains that bind antigens in a pH-sensitive manner are provided.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: January 18, 2022
    Assignee: Regeneran Pharmaceuticals, Inc.
    Inventors: John McWhirter, Lynn Macdonald, Joel H. Martin, Andrew J. Murphy
  • Patent number: 11219644
    Abstract: Embodiments of the disclosure encompass adoptive immunotherapy related to cells expressing multiple chimeric antigen receptors (CARs). In specific embodiments, T cells express a HER2-specific CAR, an IL13 R?2-specific CAR, and an EphA2-specific CAR. In particular embodiments, the cells are utilized for cancer treatment, including for glioblastoma.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: January 11, 2022
    Assignee: Baylor College of Medicine
    Inventors: Nabil M. Ahmed, Kevin Bielamowicz, Kristen Fousek
  • Patent number: 11192949
    Abstract: A method for inducing an immune response against HIV in a subject includes the step of preparing an HIV-1 gp120 envelope protein coding sequence particle having an N425K mutation, introducing the HIV-1 gp120 protein coding sequence particle having an N425K mutation into an expression construct using yeast homologous recombination, transfecting a cell with the expression construct, wherein the HIV-1 particle is secreted by the cell, and administering the secreted HIV-1 particle and a pharmaceutically acceptable carrier to the subject, wherein the secreted HIV-1 particle stimulates an immune response in the subject.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: December 7, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Eric J. Arts, Annette Burkhouse
  • Patent number: 11180763
    Abstract: Provided is an SgRNA combination, comprising an SgRNA specifically targeting the GGTA1 gene, an SgRNA specifically targeting the CMAH gene and an SgRNA specifically targeting the ?4GalNT2 gene. Also provided is a CRISPR/Cas9 vector combination, comprising a GGTA1-CRISPR/Cas9 vector, a CMAH-CRISPR/Cas9 vector and a ?4GalNT2-CRISPR/Cas9 vector. Also provided is an applicaton of the CRISPR/Cas9 vector combination in knocking out the GGTA1 gene, the CMAH gene and the ?4GalNT2 gene. The knockout rates of the three genes with the specifically targeted SgRNA sequences are respectively 56%, 63%, and 41%. A three genes knockoutpig can be obtained, wherein the three genes related to immune rejectionare knocked out, and heart valves of said pig can be acquired.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: November 23, 2021
    Assignee: Nanjing Genefriend-Biotech Inc.
    Inventors: Yifan Dai, Haiyuan Yang, Ying Wang